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OBJECTIVE—To date, there are no data investigating the
effects of GABAA activation on counterregulatory responses
during repeated hypoglycemia in humans. The aim of this study
was to determine the effects of prior GABAA activation using the
benzodiazepine alprazolam on the neuroendocrine and auto-
nomic nervous system (ANS) and metabolic counterregulatory
responses during next-day hypoglycemia in healthy humans.
RESEARCH DESIGN AND METHODS—Twenty-eight healthy
individuals (14 male and 14 female, age 27  6 years, BMI 24 
3 kg/m
2, and A1C 5.2  0.1%) participated in four randomized,
double-blind, 2-day studies. Day 1 consisted of either morning
and afternoon 2-h hyperinsulinemic euglycemia or 2-h hyperin-
sulinemic hypoglycemia (2.9 mmol/l) with either 1 mg alprazolam
or placebo administered 30 min before the start of each clamp.
Day 2 consisted of a single-step hyperinsulinemic-hypoglycemic
clamp of 2.9 mmol/l.
RESULTS—Despite similar hypoglycemia (2.9  1 mmol/l) and
insulinemia (672  108 pmol/l) during day 2 studies, GABAA
activation with alprazolam during day 1 euglycemia resulted in
signiﬁcant blunting (P  0.05) of ANS (epinephrine, norepineph-
rine, muscle sympathetic nerve activity, and pancreatic polypep-
tide), neuroendocrine (glucagon and growth hormone), and
metabolic (glucose kinetics, lipolysis, and glycogenolysis) coun-
terregulatory responses. GABAA activation with alprazolam dur-
ing prior hypoglycemia caused further signiﬁcant (P  0.05)
decrements in subsequent glucagon, growth hormone, pancreatic
polypeptide, and muscle sympathetic nerve activity counterregu-
latory responses.
CONCLUSIONS—Alprazolam activation of GABAA pathways
during day 1 hypoglycemia can play an important role in regu-
lating a spectrum of key physiologic responses during subse-
quent (day 2) hypoglycemia in healthy man. Diabetes 59:
1074–1081, 2010
H
ypoglycemia continues to be the major limiting
factor to good glycemic control in patients with
diabetes. During the last two decades, there
have been many studies demonstrating that
antecedent hypoglycemia can blunt counterregulatory re-
sponses to subsequent hypoglycemia in healthy and type 1
and type 2 diabetic individuals (1). Despite the clinical
importance and many elegant studies addressing this
topic, there remain gaps in our knowledge regarding the
mechanisms regulating neuroendocrine and autonomic
nervous system (ANS) responses during episodes of re-
peated hypoglycemia in man.
The three major acute neuroendocrine/ANS counter-
regulatory defenses against a falling plasma glucose in-
clude release of glucagon and epinephrine combined with
inhibition of endogenous insulin release. All of these
mechanisms either fail (i.e., insulin modulation and gluca-
gon release within 5 years of type 1 diabetes duration) or
become substantially reduced with disease duration (type
2 diabetes). Furthermore, repeated hypoglycemia has been
demonstrated to reduce epinephrine and glucagon re-
sponses, which are important defenses against subsequent
falling blood glucose levels in both type 1 (epinephrine)
and type 2 (epinephrine and glucagon) diabetes (2).
For many years, the problem of severe or frequent
hypoglycemia was thought to be conﬁned almost exclu-
sively to type 1 diabetes. Recent multicenter trials aimed
at improving glycemic control both within hospitals and in
the community have identiﬁed excess adverse events and
death plausibly related to hypoglycemia in type 2 diabetes
(3,4). The glucagon response to hypoglycemia is initially
relatively preserved in type 2 diabetes (although there is
decrease with disease duration) (5). However, as the
prevalence of hypoglycemia is increasing in type 2 diabe-
tes, it continues to be of importance to understand the
mechanisms regulating release of both glucagon and epi-
nephrine during repeated episodes of hypoglycemia.
-Aminobytyric acid (GABA) is a major inhibitory neu-
rotransmitter. Previous studies have demonstrated in-
creases in GABAergic tone within the ventromedial
hypothalamus in rats with repeated hypoglycemia, which
is associated with blunted glucagon and epinephrine re-
sponses (6). Chan et al. (7) have also demonstrated that
blockade of GABAA receptors within the ventromedial
hypothalamus in rats results in increased glucagon and
epinephrine responses during hypoglycemia. Studies in-
vestigating the effects of GABAA modulation on counter-
regulatory responses during hypoglycemia in humans are
scarce. In fact, previous studies have used activation of
GABAA receptors rather than changes in GABA concen-
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ANS and neuroendocrine counterregulatory responses
during hypoglycemia in humans and primates. van Vugt et
al. (8) demonstrated that alprazolam (a potent pharmaco-
logic activator of the benzodiazepine-GABAA receptor)
can inhibit anterior pituitary neuroendocrine responses
during acute hypoglycemia in rhesus monkeys. Giordano
et al. (9) reported that alprazolam also reduced neuroen-
docrine and epinephrine responses to acute intravenous
insulin bolus–induced hypoglycemia in healthy humans.
Breier et al. (10), using a model of 2-deoxyglycose–
induced glucoprivic stress in humans, also demonstrated
that alprazolam blunted ACTH and epinephrine responses
during neuroglycopenia. Lastly, Smith et al. (11), using
modaﬁnil to acutely lower GABA levels during clamped
hypoglycemia in healthy humans, reported increased heart
rate and improved cognitive function with the drug. Thus,
available data would indicate that GABAA activation can
acutely reduce, whereas GABAA blockade can increase,
neuroendocrine and sympathoadrenal responses to hypo-
glycemia. However, it is unknown whether GABAA activa-
tion can play a mechanistic role in causing neuroendocrine
and ANS failure during repeated hypoglycemia in healthy
humans. Therefore, in the present study, we have tested
the hypothesis that antecedent pharmacologic activation
of benzodiazepine-GABAA receptors with alprazolam can
result in counterregulatory failure during next-day hypo-
glycemia in healthy humans.
RESEARCH DESIGN AND METHODS
Twenty-eight healthy individuals (14 male and 14 female, aged 27  6 years,
BMI 24  3 kg/m
2, and A1C 5.2  0.1%) were studied. Subjects were
nonsmokers, had no family history of diabetes, and were not taking any
medications. All subjects had normal liver, renal, and hematological parame-
ters. Studies were approved by the Vanderbilt University Human Subjects
Institutional Review Board, and all subjects gave informed written and verbal
consent.
Experimental design. The volunteers participated in four separate, random-
ized, double-blind 2-day experiments, with differing day 1 protocols, separated
by at least 2 months (Fig. 1). Women were studied at the same point in their
menstrual cycle for each arm of the study so as to reduce variability
associated with phase of menstrual cycle. All subjects were instructed to
avoid intense exercise and alcohol and to consume their usual weight-
maintaining diet for 3 days before each study. Each subject was admitted to
the Vanderbilt University Clinical Research Center the evening before an
experiment. The next morning, after an overnight 10-h fast, subjects had
intravenous cannulae placed into each arm under local 1% lidocaine anesthe-
sia. One cannula was placed in a retrograde fashion into a vein in the back of
the hand. This hand was placed in a heated box (55–60°C) so that arterialized
blood could be obtained (12). The other cannula was placed in the contralat-
eral arm for infusions of dextrose, insulin, potassium chloride, and labeled
glucose.
Day 1 consisted of different antecedent challenges (morning and afternoon
hypoglycemia or euglycemia with or without prior [30 min before each clamp]
administration of 1 mg alprazolam or placebo in a randomized double-blind
manner) (Fig. 1). Day 1 studies consisted of a baseline period (0–120 min) and
a 2-h hyperinsulinemic experimental clamp period (120–240 min). An insulin-
infusion solution was prepared with normal saline containing 3% (vol/vol) of
the subject’s own plasma. At the onset of the experimental period, a primed
continuous infusion of insulin (Eli Lilly, Indianapolis, IN) was administered at
a rate of 9 pmol  kg
1  min
1 for 120 min (Medfusion 3010; Medex-A Furon
Healthcare Company, Deluth, GA). Potassium chloride (5 mmol/h; Imed
pump) was also infused during the clamp period to reduce insulin-induced
hypokalemia. Plasma glucose levels were measured every 5 min, and a
variable infusion of 20% dextrose was adjusted so that plasma glucose levels
were held constant (13) in the prior euglycemia studies. During hypoglycemia,
the rate of fall of glucose was controlled (0.08 mmol/min) and the hypogly-
cemic nadir (3.0 mmol/l) was achieved and held constant using a modiﬁcation
of the glucose clamp technique (14). After completion of the initial 2-h test
period, plasma glucose was maintained at euglycemia for 2 h. At that point,
insulin was restarted, and a second hyperinsulinemic-euglycemic clamp, or
hyperinsulinemic-hypoglycemic clamp, identical to that of the morning’s study
was performed (i.e., 1 mg alprazolam or placebo administered 30 min before
the start of glucose clamp). At completion of the second glucose clamp,
Experimental Protocol
Plasma Glucose 5.0 mmol/L
Day 1
Protocol 1
n=16
Protocol 3
n=16
Glucose  2.9 mmol/L Glucose 5.0 mmol/L
Day 2
Insulin 9.0 pmol/kg/min
Glucose 5.0 mmol/L
Microneurography
0 2 4 6 8hrs
3H3 Tritiated Glucose
02 4 h r s
Protocol 4
n=10
Protocol 2
n=16
Alprazolam 1 mg
tab orally 
Alprazolam 1 mg
tab orally 
Alprazolam 1 mg
tab orally 
Alprazolam 1 mg
tab orally 
Glucose 5.0 mmol/L
Insulin 9.0 pmol/kg/min
Glucose  2.9 mmol/L
Insulin 9.0 pmol/kg/min
Insulin 9.0 pmol/kg/min
Insulin 9.0 pmol/kg/min
Glucose 2.9 mmol/L
FIG. 1. Study procedures.
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and remained in the Clinical Research Center.
Day 2 hypoglycemia. Day 2 was identical for all four protocols and was
started after an overnight 10-h fast. Each study consisted of a tracer
equilibration period (0–90 min), a basal period (90–120 min), and a 2-h
experimental period (120–240 min). A primed (18 Ci) continuous infusion
(0.18 Ci/min) of high-pressure liquid chromatography–puriﬁed [3-3H] glu-
cose (11.5 mCi/mmol/l; Perkin Elmer Life Sciences, Boston, MA) was admin-
istered starting at 0 min and continued throughout the study for measurement
of glucose kinetics. Also during the equilibration period, isolation of the
peroneal nerve for microneurography (technique described below) was
started. At the onset of the experimental period, a primed constant (9 pmol 
kg
1  min
1) infusion of insulin was started and continued for the next 2 h.
The rate of fall of glucose was controlled (0.08 mmol/min), and the
hypoglycemic nadir (2.9–3.0 mmol/l) was achieved and then held constant for
the remainder of the study.
Tracer calculations. Glucose Ra, endogenous glucose production (EGP),
and glucose utilization (Rd) were calculated according to the methodology of
Wall et al. (15). EGP was calculated by determining the total Ra (which
comprises both EGP and any exogenous glucose infused to maintain the
desired hypoglycemia) and subtracting from it the amount of exogenous
glucose infused. It is now recognized that this approach is not fully quantita-
tive because it underestimates the total Ra and Rd that can be obtained. The
use of a highly puriﬁed tracer and taking measurements under steady-state
conditions (i.e., constant speciﬁc activity) in the presence of low glucose ﬂux
eliminates most, if not all, of the problems. To minimize changes in speciﬁc
activity, isotope delivery was increased commensurate with increases in
exogenous glucose infusion. For this study, only glucose ﬂux results from the
basal and the ﬁnal 30-min periods of the hypoglycemic clamps are reported.
Direct measurement of muscle sympathetic nerve activity via micro-
neurography. Muscle sympathetic nerve activity (MSNA) was recorded
because it provides a measurement of direct sympathetic nervous system
activity during insulin-induced hypoglycemia (16). MSNA was measured in the
peroneal nerve at the level of the ﬁbular head or popliteal fossa. A recording
of MSNA was considered adequate when there was 1) spontaneous appear-
ance of pulse-linked bursts, 2) increased nerve activity during phase II
(hypotensive phase) and suppressed activity during phase IV (blood pressure
overshoot) of the Valsalva maneuver, 3) increased nerve activity in response
to held expiration (apnea), or 4) proprioceptive afferent signals in response to
stretching the tendons in the foot or tapping the muscle belly but not
cutaneous stimulation by stroking the skin.
Sympathetic nerve activity was expressed as bursts per minute. Measure-
ments of MSNA were made from original tracings or online recordings
(DI-220; Dataq Instruments, Akron, OH) by an operator blinded to the
sequence of experiments. Bursts were selected if the signal:noise ratio was
2:1.
Analytical methods. The collection and processing of blood samples have
previously been described (17). Plasma glucose concentrations were mea-
sured in triplicate using the glucose oxidase method with a glucose analyzer
(Beckman, Fullerton, CA). Blood for hormones and intermediary metabolites
were drawn twice during the basal period and every 15 min during the
experimental period. Glucagon was measured according to the method of
Aguilar-Parada et al. (18), with an interassay coefﬁcient of variation (CV) of
15%. Insulin was measured as previously described (19), with an interassay CV
of 11%. Catecholamines were determined by high-pressure liquid chromatog-
raphy (20), with an interassay CV of 12% for both epinephrine and norepi-
nephrine. We made two modiﬁcations to the procedure for catecholamine
determination: 1) we used a ﬁve-point rather than one-point standard calibra-
tion curve, and 2) we spiked the initial and ﬁnal samples of plasma with
known amounts of epinephrine and norepinephrine so that accurate identiﬁ-
cation of the relevant catecholamine peaks could be made. Growth hormone
(21) (interassay CV 8%), cortisol (Clinical Assays Gamma Coat Radioimmu-
noassay kit) (interassay CV 6%), pancreatic polypeptide (interassay CV 8%)
(22), and glucagon (Linco Research, St. Louis, MO) (interassay CV 15%) were
measured using radioimmunoassay techniques. Lactate and -hydroxybu-
tyrate were measured on deproteinized whole blood using the methodology of
Lloyd et al. (23). Nonesteriﬁed fatty acids (NEFAs) were measured using a
WAKO kit (24).
Cardiovascular parameters. Heart rate and systolic, diastolic, and mean
arterial blood pressure were measured noninvasively by a Dinamap (Critikon,
Tampa, FL) every 10 min throughout each 2-h insulin clamp. Hypoglycemic
symptoms were quantiﬁed using a previously validated semiquantitative
questionnaire (25). Each individual was asked to rate his or her experience of
the symptoms twice during the control period and every 15 min during
experimental periods. Symptoms measured included the following: sweaty,
tremor/shaky, hot, thirsty/dry mouth, agitation/irritability, palpitations, tired/
fatigued, confusion, dizzy, difﬁculty thinking, blurriness of vision, and sleepy.
The ratings of the ﬁrst six symptoms were summed to get the autonomic score
while the ratings from the last six symptoms provide a neuroglycopenic
symptom score.
Statistical analysis. Data are expressed as means  SE and were analyzed
using standard parametric one- and two-way ANOVA with repeated measures
where appropriate (SigmaStat; SPSS Science, Chicago, IL). Tukey’s post hoc
analysis was used to delineate statistical signiﬁcance across time within each
group and for each group compared with the prior euglycemia control group.
A P value of 0.05 was accepted as statistically signiﬁcant. The baseline and
ﬁnal 30 min of hypoglycemia on day 2 were compared for most parameters
because steady-state glucose levels, insulin levels, and glucose infusion rates
were achieved by this time. Baseline period data represent an average of two
time points (110 and 120 min), and ﬁnal 30-min data represent an average of
three measurements taken during this time (210, 225, and 240 min).
RESULTS
Day 1 glucose and insulin levels. Plasma glucose levels
were similar in the morning and afternoon during the prior
euglycemic studies with and without alprazolam (5.2  0.1
mmol/l). Plasma glucose during the day 1 morning and
afternoon hypoglycemia studies were also similar with and
without alprazolam (2.9  0.1 mmol/l). Plasma insulin
levels were similar among all groups during the morning
and afternoon hyperinsulinemic-euglycemic and -hypogly-
cemic clamps (672  108 pmol/l).
Day 2 glucose, insulin, and neuroendocrine counter-
regulatory hormones. Plasma glucose was equivalent
(2.9  0.1 mmol/l) during all of day 2 hypoglycemia.
Plasma insulin was also similar (612  58 pmol/l) during
all of day 2 hypoglycemia studies (Fig. 2).
Plasma glucagon levels (Fig. 3) were signiﬁcantly re-
duced (P  0.01) during the ﬁnal 30 min of day 2
hypoglycemia following day 1 euglycemia and alprazolam
(131  21 ng/l) and day 1 hypoglycemia (132  18 ng/l)
compared with day 1 euglycemia (241  34 ng/l). Day 1
hypoglycemia and alprazolam resulted in a greater reduc-
tion (P  0.05) in day 2 glucagon (76  8 ng/l) than that in
the other groups during day 2 hypoglycemia.
Day 2 growth hormone responses were also lower (P 
0.05) following day 1 euglycemia and alprazolam (20  4
g/l) than those of day 1 euglycemia (31  5 g/l) or day
1 hypoglycemia (28  4 g/l). Growth hormone responses
were further reduced (P  0.05) following day 1 hypogly-
cemia and alprazolam (13  3 g/l) compared with those
of day 1 hypoglycemia and day 1 hypoglycemia and
alprazolam (Fig. 3). Day 2 plasma cortisol responses were
similar in all groups following the differing day 1
interventions.
ANS responses during day 2 hypoglycemia. Day 2
plasma epinephrine levels (Fig. 4) were signiﬁcantly lower
(P  0.05) during the ﬁnal 30 min of hypoglycemia
following day 1 euglycemia and alprazolam (3,397  339
pmol/l), day 1 hypoglycemia (2,230  290 pmol/l), and day
1 hypoglycemia and alprazolam (2,943  515 pmol/l) than
those of day 1 euglycemia (4,209  389 pmol/l).
Day 2 baseline and ﬁnal 30 min of hypoglycemia norepi-
nephrine values (Fig. 4) were also signiﬁcantly lower (P 
0.05) following day 1 euglycemia and alprazolam (0.7  0.1
and 1.2  0.16 nmol/l, respectively) and day 1 hypoglyce-
mia and alprazolam (0.6  0.1 and 1.5  0.15 nmol/l) than
those of day 1 euglycemia (1.1  0.1 and 1.9  0.17 nmol/l).
Pancreatic polypeptide levels during the ﬁnal 30 min of
day 2 hypoglycemia were also signiﬁcantly lower (P 
0.05) after day 1 euglycemia and alprazolam (163  27
pmol/l), day 1 hypoglycemia (197  28 pmol/l), and (P 
0.01) day 1 hypoglycemia and alprazolam (128  32
pmol/l) than those of day 1 euglycemia (263  33 pmol/l).
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greater extent (P  0.05) following day 1 alprazolam and
hypoglycemia compared with day 1 hypoglycemia and day
1 euglycemia.
Basal MSNA (Fig. 5) was signiﬁcantly reduced (P  0.05)
following day 1 alprazolam administration. MSNA responses
during the ﬁnal 30 min of day 2 hypoglycemia were also
reduced following day 1 euglycemia and alprazolam (	3  1
bursts/min) and day 1 hypoglycemia (	7  2 bursts/min)
compared with those (	12  2) following day 1 euglycemia.
MSNA responses were blunted by a greater extent (P  0.05)
following day 1 hypoglycemia and alprazolam (	2  1
bursts/min) than those of day 1 euglycemia and alprazolam,
day 1 hypoglycemia, or day 1 euglycemia.
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reduced (P  0.05) during the ﬁnal 30 min of day 2
hypoglycemia following day 1 euglycemia and alprazolam,
day 1 hypoglycemia, and day 1 hypoglycemia and alprazo-
lam (7.2  1.7, 6.1  1.6, and 8.8  1.1 mol  kg
1  min
1,
respectively) with those of day 1 euglycemia (12.2  1.7
mol  kg
1  min
1) (Table 1). Glucose infusion rates were
signiﬁcantly increased (P  0.05) during the ﬁnal 30 min of
day 2 hypoglycemia following day 1 euglycemia and alpra-
zolam, day 1 hypoglycemia, and day 1 hypoglycemia and
alprazolam (7.5  1.1, 8.8  3.3, and 8.3  2.2 mol  kg
1 
min
1, respectively) compared with 2.5  1.1 mol  kg
1 
min
1 following day 1 euglycemia.
Day 2 intermediary metabolism. Blood lactate levels
were signiﬁcantly reduced (P  0.05) basally and during
the ﬁnal 30 min of day 2 hypoglycemia following day 1
euglycemia and alprazolam and day 1 hypoglycemia and
alprazolam compared with day 1 euglycemia (Table 2).
Plasma NEFA levels were also signiﬁcantly reduced (P 
0.05) at baseline and during the ﬁnal 30 min of hypoglyce-
mia following both day 1 alprazolam groups. NEFA levels
were also reduced (P  0.05) during the ﬁnal 30 min of day
2 hypoglycemia following day 1 hypoglycemia (Table 2).
Day 2 cardiovascular responses and symptom re-
sponses. There were similar changes in blood pressure
(systolic, diastolic, and mean arterial pressure) and heart
rate during the ﬁnal 30 min of hypoglycemia in all groups
(Table 3). Hypoglycemic symptoms were reduced in all
groups during the ﬁnal 30 min of day 2 hypoglycemia.
Following day 1 euglycemia and alprazolam, symptoms
were reduced by 25%, which did not reach statistical
signiﬁcance. Following day 1 hypoglycemia and alprazo-
lam and day 1 hypoglycemia, there were signiﬁcant reduc-
tions (P  0.05) of 30 and 38%, respectively. Day 2
autonomic and neuroglycopenic symptom scores were
similarly reduced following day 1 hypoglycemia or day 1
hypoglycemia and alprazolam.
DISCUSSION
This study tested the hypothesis that day 1 pharmacologic
activation of GABAA receptors in healthy man with alpra-
zolam can blunt neuroendocrine and ANS responses to
day 2 hypoglycemia. Our results demonstrate that prior
GABAA receptor activation with alprazolam has wide-
spread effects to blunt anterior pituitary, sympatho-
adrenal, parasympathetic, and sympathetic neural coun-
terregulatory responses to next-day hypoglycemia. GABAA
activation resulted in signiﬁcant blunting of a spectrum of
key neuroendocrine, ANS, and metabolic counterregula-
tory responses/mechanisms (glucagon, epinephrine, en-
dogenous glucose production, and lipolysis) during next-
day hypoglycemia.
Numerous studies have investigated the mechanisms re-
sponsible for the acquired ANS and neuroendocrine counter-
regulatory failure occurring following hypoglycemia (1). To
date, a unifying mechanism responsible for the syndrome of
acquired hypoglycemia-associated counterregulatory failure
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neurotransmitter and is known to regulate many physiologic
responses (27–29). Previous work has demonstrated that
increases of gabergic tone in the ventromedial nucleus in rats
can downregulate counterregulatory responses to hypogly-
cemia and indeed subsequent hypoglycemia (6). Additionally,
blockade of GABAA in the ventromedial nucleus of rats
increases neuroendocrine and sympathetic nervous system
responses to hypoglycemia (7). Determination of the effects
of activation of speciﬁc gabergic neurons in discrete areas of
the human brain is not possible at this time. To overcome this
limitation, previous studies have used alprazolam, a com-
monly used anxiolytic to speciﬁcally activate brain benzodi-
azepine-GABAA receptors (8,9). Two previous studies (one in
primates and the other in healthy humans) have demon-
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FIG. 5. MSNA and hypoglycemia symptoms at baseline (gray boxes) and during ﬁnal 30 min (black boxes) of day 2 hypoglycemia in healthy
individuals fasted overnight following either day 1 euglycemia (Eugly), day 1 euglycemia and alprazolam (EuglyAlp), day 2 hypoglycemia
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TABLE 1
Rates of endogenous glucose production, glucose disappearance,
and glucose infusion during baseline and ﬁnal 30 min of hypo-
glycemia in men fasted overnight following day 1 euglycemia,
day 1 euglycemia and alprazolam, day 1 hypoglycemia, and day 1
hypoglycemia and alprazolam
Baseline
period
Final 30 min
hypoglycemia
Endogenous glucose production
(mol  kg
1  min
1)
Euglycemia 9.9  0.6 13.2  1.7*
Euglycemia and alprazolam 9.9  1.1 7.2  1.7*†
Hypoglycemia 11.6  0.6 6.1  1.7*†
Hypoglycemia and alprazolam 11.0  1.1 8.8  1.1*†
Rd (mol  kg
1  min
1)
Euglycemia 10.5  2.2 15.6  1.7*
Euglycemia and alprazolam 9.9  0.6 14.8  1.7*
Hypoglycemia 11.6  1.7 14.9  1.1*
Hypoglycemia and alprazolam 10.5  1.1 17.1  1.7*
Glucose infusion rate
(mol  kg
1  min
1)
Euglycemia 0 2.5  1.1
Euglycemia and alprazolam 0 7.5  1.1†
Hypoglycemia 0 8.8  3.3†
Hypoglycemia and alprazolam 0 8.3  2.2†
*P  0.05: signiﬁcantly different from baseline. †P  0.05: signiﬁ-
cantly different from euglycemic controls.
TABLE 2
Intermediary metabolite levels during baseline and ﬁnal 30 min of
hyperinsulinemic hypoglycemia in healthy individuals fasted
overnight following day 1 euglycemia, day 1 euglycemia and
alprazolam, day 1 hypoglycemia, and day 1 hypoglycemia and
alprazolam
Baseline
period
Final 30 min
hypoglycemia
Blood lactate (mmol/l)
Euglycemia 0.9  0.1 1.4  0.1*
Euglycemia and alprazolam 0.6  0.1† 1.1  0.1*‡
Hypoglycemia 0.9  0.1 1.4  0.1*
Hypoglycemia and alprazolam 0.6  0.1† 0.9  0.1*‡
Plasma NEFA (mol/l)
Euglycemia 329  43 147  22*
Euglycemia and alprazolam 174  27† 80  12*‡
Hypoglycemia 346  31 98  23*†
Hypoglycemia and alprazolam 186  40† 73  21*‡
Blood -hydroxybutyrate (mol/l)
Euglycemia 40  20 10  4*
Euglycemia and alprazolam 70  10 33  20*
Hypoglycemia 30  89  2*
Hypoglycemia and alprazolam 20  10 10  5*
*P  0.05 signiﬁcantly different from baseline. †P  0.05 signiﬁcantly
different from euglycemia and hypoglycemia. ‡P  0.05 signiﬁcantly
different from euglycemia.
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docrine and sympathetic nervous system responses during
intravenouos insulin bolus–induced hypoglycemia (8,9). In
the present study, prior GABAA activation with alprazolam
during day 1 euglycemia resulted in signiﬁcant reductions in
ANS and neuroendocrine responses during next-day hypo-
glycemia. Multiple limbs of the ANS response to hypoglyce-
mia were blunted by prior GABAA activation. Epinephrine,
norepinephrine, MSNA, and hypoglycemic symptoms were
reduced, indicating a diffuse blunting effect upon the sympa-
thetic nervous system. Furthermore, basal sympathetic neu-
ral outﬂow was also reduced by prior GABAA activation.
Additionally, pancreatic polypeptide, a marker of parasym-
pathetic nervous system activity, was also signiﬁcantly re-
duced. The site of GABAA sensing to downregulate the ANS
responses cannot be precisely determined in this study. The
down regulation of MSNA responses points to central ner-
vous system sensing. However, there are GABAA receptors in
islet cells that may be regulating the pancreatic polypeptide
and glucagon responses. Additionally, previous work has
demonstrated that GABAA receptors may also modulate
catecholamine secretion directly from the adrenal medulla
(30). Day 1 GABAA activation with alprazolam also reduced
the response of growth hormone and glucagon during day 2
hypoglycemia. The regulation of glucagon release during
hypoglycemia is still under study. Previous work has pro-
vided evidence for local control (i.e., within the pancreatic
islets) of glucagon release secondary to inhibition of -cell
insulin release (31). Other studies have pointed to regulation
via the ANS (32). In the present study, we cannot deﬁnitively
state whether prior activation of GABAA inhibited glucagon
release via a direct effect on pancreatic islets or via inhibition
of neural (presumably ANS) pathways.
Similar to the ﬁndings of Giodano et al. (7) in humans
and Chan et al. (8) in rats, we did not ﬁnd signiﬁcant
reductions of cortisol during hypoglycemia following al-
prazolam. However, both Breir et al. (10), using 2-deoxyg-
lycose glucose to create a glucoprivic state in humans, and
Giodano et al. (9) reported that ACTH levels were blunted
during hypoglycemia following acute GABAA activation
with alprazolam. We did not measure ACTH in the current
study, but our ﬁnding that growth hormone responses
were blunted following alprazolam supports previous ﬁnd-
ings that GABAA activation can blunt hypothalamo-ante-
rior pituitary responses during hypoglycemia in humans.
Important metabolic counterregulatory responses/
mechanisms were also blunted by GABAA activation.
Endogenous glucose production, lipolysis (as reﬂected by
NEFA levels), and glycogenolysis (as reﬂected by lactate
levels) were blunted during day 2 hypoglycemia following
alprazolam. These reduced metabolic counterregulatory
responses during day 2 hypoglycemia can be explained by
the blunted ANS and neuroendocrine drive caused by the
GABAA activation. The reduced day 2 basal NEFA and
lactate levels following day 1 alprazolam may also be
explained by the observed reduced sympathetic neural
activity (i.e., reduced lipolysis and glycogenolysis) (27).
Blood pressure and heart rate responses were not different
during day 2 hypoglycemia in any of the groups despite the
differences in ANS activity. The mechanism for this ﬁnding
is not known but may be explained by offsetting effects of
GABAA activation on the sympathetic and parasympa-
thetic nervous system.
This present study also studied whether activation of
GABAA receptors during prior hypoglycemia had any addi-
tional effects on subsequent counterregulatory responses.
Our results do demonstrate that pharmacologic activation of
GABAAreceptors during prior hypoglycemia with alprazolam
results in additional blunting of some counterregulatory
responses. Epinephrine and norepinephrine responses were
not further blunted during day 2 hypoglycemia by the addi-
tion of alprazolam during day 1 hypoglycemia. Additionally,
important metabolic counterregulatory mechanisms such as
glucose kinetics (EGP, glucose disappearance, and lipolysis)
were not farther decreased by the combination of hypogly-
cemia and GABAA activation). However, MSNA, glucagon,
pancreatic polypeptide, and growth hormone responses
were further reduced following day 1 hypoglycemia and
alprazolam. We believe that there may be two possible
explanations for this ﬁnding: 1) the combination of hypogly-
cemia and alprazolam resulted in greater activation of
GABAA receptors or 2) prior alprazolam and hypoglycemia
operate through different mechanisms for which the com-
bined effects are additive. Our results also suggest that
blunted counterregulatory responses are not due to exhaus-
tion of individual neuroendocrine hormones and that the
ANS response to hypoglycemia is heterogeneous, with some
elements more susceptible to downregulation following cer-
tain stimuli (i.e., GABAA activation) than others (in this
study, MSNA and parasympathetic nervous system were
more susceptible than adrenomedullary and symptom re-
sponses). Lastly, although this is a study investigating phys-
iologic responses to hypoglycemia in healthy subjects, it may
be useful to discuss the possible clinical implications of our
study. Benzodiazepines are commonly used in the clinical
management of patients with diabetes. The ﬁndings that
alprazolam can signiﬁcantly reduce key neuroendocrine and
ANS counterregulatory responses during next-day hypogly-
cemia and that the combination of prior hypoglycemia with
TABLE 3
Cardiovascular responses during baseline and ﬁnal 30 min of
hyperinsulinemic hypoglycemia in men fasted overnight follow-
ing day 1 euglycemia, day 1 euglycemia and alprazolam, day 1
hypoglycemia, and day 1 hypoglycemia and alprazolam
Baseline
period
Final 30 min
hypoglycemia
Monthly systolic blood pressure
(mmHg)
Euglycemia 111  3 119  4*
Euglycemia and alprazolam 116  4 126  5*
Hypoglycemia 114  3 123  4*
Hypoglycemia and alprazolam 120  6 131  9*
Monthly diastolic blood
pressure (mmHg)
Euglycemia 69  36 2  2*
Euglycemia and alprazolam 73  36 8  3*
Hypoglycemia 67  36 8  4*
Hypoglycemia and alprazolam 73  36 6  4*
Monthly mean arterial pressure
(mmHg)
Euglycemia 82  47 8  4
Euglycemia and alprazolam 82  37 9  4
Hypoglycemia 81  27 9  2
Hypoglycemia and alprazolam 85  48 3  5
Heart rate (bpm)
Euglycemia 63  37 6  5*
Euglycemia and alprazolam 62  37 2  4*
Hypoglycemia 65  47 5  4*
Hypoglycemia and alprazolam 65  37 4  3*
*P  0.05 signiﬁcantly different from baseline.
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sponses raise concerns about the possible effects of benzo-
diazepines on the prevalence of hypoglycemia in clinical
practice.
The dose of alprazolam (1 mg before each of two glucose
clamps) used in the present study was relatively modest. In
the U.S., the drug is approved to be used up to a dose of 10
mg daily. The present study dose of alprazolam was typical of
usual starting doses, which range from 0.5 to 1 mg three
times a day. However, we do want to point out that the
present study was not a clinical outcomes study. We were
using alprazolam as a speciﬁc pharmacologic probe for
GABAA activation. As a result of to the present study design,
we cannot comment whether higher (or lower) doses of day
1 alprazolam would have had greater or lesser effects on day
2 counterregulatory responses. It should also be noted that
although alprazolam has a quick onset of action reaching
maximum levels within 1–2 h, the plasma half-life is longer
with a typical duration of 9–11 h. Thus, as day 2 hypoglyce-
mia was induced 21 h after the last administration of
alprazolam, it is possible that the day 1 administration of the
drug still resulted in some acute effects during subsequent
(day 2) hypoglycemia. However, what is clear from the
present study is that submaximal activation of GABAA recep-
tors can result in rapid and widespread downregulation of
subsequent homeostatic responses to hypoglycemia in
healthy man.
In summary, this study has demonstrated that prior
activation of GABAA receptors by alprazolam can produce
a spectrum of reduced ANS (adrenomedullary, direct
sympathetic nerve activity, and parasympathetic nervous
system), neuroendocrine (growth hormone and glucagon),
and metabolic (endogenous glucose production, lipolysis,
and glycogenolysis) counterregulatory responses during
next-day hypoglycemia. We conclude that prior activation
of GABAA pathways can play an important role in regulat-
ing a number of key physiologic responses to subsequent
hypoglycemia in healthy man. Further studies are required
to determine whether GABAA receptors exert similar
effects in individuals with diabetes.
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